Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Harrow Health, Inc.NASDAQ: HROW
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 41.8% from a year ago
Cash & equivalents stood at $94.64M at the end of Q1 FY2026, up 41.8% from a year earlier and up 29.8% from the prior quarter. Over 3 fiscal years it compounded at -8.8% a year.
Context
- Cash & equivalents amounted to 22.6% of total assets at the end of Q1 FY2026, up 4.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +41.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 72.93M USD
- Year-over-year change
- +54.4%
- 4-year CAGR
- +14.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 72.93M | +54.4% |
| FY2024 | 2024-12-31 | 47.25M | -36.2% |
| FY2023 | 2023-12-31 | 74.09M | -23.0% |
| FY2022 | 2022-12-31 | 96.27M | +128.3% |
| FY2021 | 2021-12-31 | 42.17M | — |
Cash & Equivalents vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +41.8% is the 2nd highest of 8, against a peer median of +21.1%.
- Cash & equivalents amounts to 22.6% of total assets for HROW, versus a peer median of 31.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $666.7M USD | +90.7% | +93.1% | 91.0% | |
| Jun 2026 | $367M USD | +34.9% | +0.3% | 2.6% | |
| Sep 2026 | $136.53M USD | +21.1% | +36.8% | 27.0% | |
| Mar 2026 | $94.64M USD | +41.8% | -8.8% | 22.6% | |
| Sep 2026 | $88.68M USD | +23.1% | +3.3% | 42.3% | |
| Mar 2026 | $77.71M USD | -8.7% | +2.1% | 27.0% | |
| Mar 2026 | CHF 64.37M CHF | +7.5% | +60.2% | 26.5% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $11.22M USD | — | — | 60.2% |
| Mar 2026 | $7.75M USD | +2.5% | -22.5% | 35.4% | |
| Peer median (excluding HROW) | — | +21.1% | +3.3% | 31.2% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 42.17M | 96.27M | 74.09M | 47.25M | 72.93M |
| Short-term Investments | 8.5M | 5.59M | 8.68M | 0 | 0 |
| Net Receivables | 4.52M | 6.39M | 36.49M | 116.6M | 110.9M |
| Inventory | 4.22M | 6.54M | 10.87M | 10.7M | 13.52M |
| Other Current Assets | 92K | 118K | 1.75M | 3.41M | 2.13M |
| Total Current Assets | 60.66M | 118.26M | 139.07M | 189.65M | 211.75M |
| Property, Plant & Equipment (Net) | 9.08M | 11M | 12.44M | 12.29M | 11.04M |
| Goodwill | 332K | 332K | 332K | 332K | 332K |
| Intangible Assets | 17.13M | 25.84M | 159.91M | 186.7M | 175.17M |
| Long-term Investments | 11.13M | 0 | 0 | 0 | 0 |
| Tax Assets | (12.45M) | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.45M | 1.95M | 0 | 0 | 1.18M |
| Total Non-current Assets | 37.67M | 39.12M | 172.68M | 199.32M | 187.73M |
| Total Assets | 98.33M | 157.38M | 311.76M | 388.97M | 399.48M |
| Account Payables | 5.17M | 6.44M | 21.42M | 38.76M | 35.36M |
| Short-term Debt | 0 | 0 | 806K | 0 | 887K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 16K | 113K | 0 | 44K | 788K |
| Other Current Liabilities | 1.16M | 0 | 21.66M | 0 | 59.27M |
| Total Current Liabilities | 9.72M | 18.63M | 49.34M | 91.34M | 96.3M |
| Long-term Debt | 71.65M | 104.17M | 183.17M | 219.54M | 243.18M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 2.71M | 0 | 0 |
| Total Non-current Liabilities | 77.68M | 111.51M | 192.41M | 228.33M | 251.09M |
| Total Liabilities | 87.4M | 130.14M | 241.75M | 319.67M | 347.39M |
| Common Stock | 27K | 30K | 35K | 35K | 37K |
| Retained Earnings | (95.41M) | (109.49M) | (133.9M) | (151.39M) | (156.52M) |
| Accumulated OCI | 0 | 0 | (409K) | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (355K) | (355K) | (355K) | (355K) | (355K) |
| Total Equity | 10.93M | 27.24M | 70M | 69.3M | 52.09M |
| Total Debt | 77.96M | 112.23M | 190.5M | 228.83M | 251.98M |
| Net Debt | 35.79M | 15.96M | 116.42M | 181.58M | 179.05M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.